Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)

Key Stats

Today's Range
$1.03
$1.03
50-Day Range
$0.94
$1.03
52-Week Range
$0.32
$1.57
Volume
N/A
Average Volume
1.93 million shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Spectrum Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

SPPI MarketRank™: 

Spectrum Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat, and ranked 952nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spectrum Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SPPI.
  • Dividend Yield

    Spectrum Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Spectrum Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SPPI.
  • Search Interest

    1 people have searched for SPPI on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spectrum Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 21.67% of the stock of Spectrum Pharmaceuticals is held by institutions.

  • Read more about Spectrum Pharmaceuticals' insider trading history.
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

SPPI Stock Analysis - Frequently Asked Questions

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF).

Company Calendar

Last Earnings
11/10/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
86
Year Founded
2002

Profitability

Net Income
$-75,400,000.00
Pretax Margin
-263.04%

Debt

Sales & Book Value

Annual Sales
$10.11 million
Book Value
$0.15 per share

Miscellaneous

Free Float
199,704,000
Market Cap
$211.41 million
Optionable
Optionable
Beta
2.15

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:SPPI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners